Usefulness of @entity2690 resistance estimation and the XXXX in predicting @entity6 .

@entity1 @entity6 @entity2690 @entity755 @entity729 @entity209 @entity731 @entity65 @entity165
@entity209 ( @entity209 ) definitions predict cardiovascular events beyond traditional risk factors in @entity1 with @entity6 ( @entity6 ) as well as subjects without @entity6 . It has been shown that @entity755 ( @entity755 ) and non-high-density lipoprotein @entity165 are associated with @entity729 in @entity6 . However, the relative value of @entity209 , @entity755 lipoproteins, and estimates of @entity2690 resistance is unknown in predicting @entity731 in @entity6 . Cross-sectional analyses of white subjects in 2 community-based studies were performed (n = 611 @entity1 with @entity6 , n = 803 subjects without @entity6 ) using multivariate analysis of traditional risk factors and then adding @entity209 , @entity755 , and homeostasis model assessment of @entity2690 resistance (HOMA-IR). Incremental value was tested using likelihood ratio testing. Beyond traditional risk, HOMA-IR (tobit regression ratio 1.86, p = 0.002), @entity755 (tobit regression ratio 1.55, p = 0.001), and @entity209 (tobit regression ratio 2.37, p = 0.007) were independently associated with @entity729 in @entity6 . In nested models, HOMA-IR added value to @entity755 (tobit regression ratio 1.72, p = 0.008), @entity209 (tobit regression ratio 1.72, p = 0.011), and @entity755 and @entity209 (tobit regression ratio 1.64, p = 0.021). @entity755 showed a similar pattern when added to HOMA-IR (tobit regression ratio 1.51, p = 0.004), @entity209 (tobit regression ratio 1.46, p = 0.005), and HOMA-IR and @entity209 (tobit regression ratio 1.48, p = 0.006). @entity209 added to @entity755 (tobit regression ratio 1.99, p = 0.032) but not HOMA-IR (tobit regression ratio 1.54, p = 0.221) or @entity755 and HOMA-IR (tobit regression ratio 1.32, p = 0.434). In conclusion, @entity2690 resistance estimates add value to @entity209 and @entity755 in predicting @entity729 scores in @entity6 and warrant further evaluation in clinic for identification of @entity1 with @entity6 at higher risk for @entity65 .
